Abstract 1796
Background
ESMO has developed a framework for evaluating the magnitude of clinical benefit (ESMO-MCBS) of new cancer therapies. We evaluate the extent to which contemporary randomized controlled trials (RCTs) are designed to detect differences in outcome that meet the proposed ESMO thresholds for clinically meaningful benefit (CMB).
Methods
All RCTs evaluating systemic therapy for breast, non-small cell (NSCLC), colorectal (CRC), and pancreas cancer published 2011-2015 were reviewed. Two authors abstracted data regarding trial characteristics and applied the ESMO-MCBS to study results. Data from the statistical methods section were used to determine if the RCT was powered to detect an effect that would meet CMB.
Results
277 eligible RCTs were included (40% breast, 31% NSCLC, 22% CRC, 6% pancreas). Median sample size was 532 and 83% were funded by industry. Among the 225 RCTs in which an ESMO design score could be assigned, 69% were powered to detect an effect size that would not meet the threshold for CMB. Factors associated with being powered for small effect size included disease (79% lung, 71% GI, 61% breast, p = 0.038), treatment intent (82% palliative, 37% curative, p
Conclusions
Less than one-third of RCTs with statistically significant results meet ESMO thresholds for clinically meaningful benefit, and this represents only 15% of all published trials. Investigators and funding agencies should adopt more stringent thresholds for meaningful benefit in the design of future RCTs.
Clinical trial identification
Legal entity responsible for the study
Queen's University
Funding
Kingston General Hospital
Disclosure
All authors have declared no conflicts of interest.